


## VEGFR-2-IN-29

Cat. No.:	HY-148040		
CAS No.:	62802-77-1		
Molecular Formula:	C <sub>16</sub> H <sub>11</sub> N <sub>3</sub> O <sub>3</sub>		
Molecular Weight:	293.28		
Target:	VEGFR		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 20 mg/mL (68.19 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
1 mM		3.4097 mL	17.0486 mL	34.0971 mL
5 mM		0.6819 mL	3.4097 mL	6.8194 mL
10 mM		0.3410 mL	1.7049 mL	3.4097 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC<sub>50</sub> of 16.5 nM<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

VEGFR-2  
16.5 nM (IC<sub>50</sub>)

#### In Vitro

VEGFR-2-IN-29 (Compound 5) (72 h) inhibits HUVEC proliferation<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
Cell Proliferation Assay<sup>[1]</sup>

Cell Line: HUVEC

Concentration:

Incubation Time: 72 h

Result: Showed inhibition with IC<sub>50</sub>s of 15.8 nM and 210 nM against VEGF- and bFGF-induced

---



---

HUVEC proliferation.

---

## REFERENCES

---

[1]. Yang Y, et al. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors. *Bioorg Med Chem Lett*. 2010 Nov 15;20(22):6653-6.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA